**Supplementary Table 5. Liver-related mortality according to fatty liver disease category in clinically relevant subgroups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Subgroup | No EAC / no FLD | EAC / no FLD | NAFLD | AFLD | *p*-value for interaction |
| Age |  |  |  |  | 0.978 |
| < 50 years (N = 370,818) | reference | 2.65 (0.98-7.13) | 1.50 (0.58-3.90) | 5.74 (2.06-16.03) |  |
| ≥ 50 years (N = 67,010) | reference | 2.27 (1.15-4.48) | 1.35 (0.74-2.45) | 4.45 (2.22-8.89) |  |
| Sex |  |  |  |  | 0.280 |
| Women (N = 204,119) | reference | 8.53 (1.90-38.34) | 1.95 (0.78-4.87) | 11.97 (1.54-93.10) |  |
| Men (N = 233,709) | reference | 2.01 (1.10-3.67) | 1.19 (0.65-2.18) | 4.22 (2.28-7.79) |  |
| Current smoking |  |  |  |  | 0.784 |
| No (N = 307,816) | reference | 2.22 (0.89-5.53) | 1.16 (0.59-2.26) | 4.60 (1.90-11.17) |  |
| Yes (N = 102,402) | reference | 2.88 (1.33-6.25) | 1.98 (0.88-4.45) | 5.61 (2.50-12.60) |  |
| Regular exercise |  |  |  |  | 0.669 |
| < 3 times/week (N=366,013) | reference | 2.89 (1.50-5.58) | 1.77 (0.98-3.20) | 5.23 (2.62-10.42) |  |
| ≥ 3 times/week (N = 63,778) | reference | 1.56 (0.51-4.77) | 0.49 (0.14-1.72) | 3.42 (1.10-10.70) |  |
| HOMA-IR |  |  |  |  | 0.387 |
| < 2.5 (N = 357,154) | reference | 2.67 (1.43-4.98) | 1.35 (0.70-2.63) | 4.90 (2.32-10.35) |  |
| ≥ 2.5 (N = 70,086) | reference | 1.06 (0.23-4.94) | 0.83 (0.34-2.02) | 3.52 (1.37-9.01) |  |
| HsCRP |  |  |  |  | 0.153 |
| <1.0 mg/l (N=321,812) | reference | 1.98 (0.82-4.76) | 2.14 (1.06-4.30) | 3.05 (1.01-9.17) |  |
| ≥1.0 mg/l (N=110,989) | reference | 2.39 (1.13-5.04) | 0.87 (0.42-1.79) | 4.89 (2.44-9.79) |  |

Cox proportional hazard models with age as a timescale were used to estimate hazard ratios (HRs) and 95 percent confidence intervals (95% CIs). Model was adjusted for sex, year of screening exam, center, BMI, smoking status, regular exercise, educational level, history of diabetes, history of hypertension and history of cancer.

Abbreviations: AFLD, alcoholic fatty liver disease; BMI, body mass index; EAC, excessive alcohol consumption; FLD, fatty liver disease; hsCRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance; NAFLD, nonalcoholic fatty liver disease.